deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06863259

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

A Phase 1 Study With a Pilot Expansion Phase of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone (IoVeX) for Relapsed B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: Children's Hospital Medical Center, Cincinnati

Conditions B-cell Acute Lymphoblastic Leukemia
Interventions Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone
Updated 3 times since 2025 Last updated: Feb 16, 2026 Started: May 21, 2025 Primary completion: Jan 1, 2028 Completion: Jan 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates B-cell Acute Lymphoblastic Leukemia and is currently actively recruiting participants. Children's Hospital Medical Center, Cincinnati leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshotNot Yet Recruiting~Jul 2025 – ~Feb 2026 · 7 months · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Jul 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  3. Apr 2025 — Jul 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Hospital Medical Center, Cincinnati
Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations